Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 24 March 2000:
Vol. 287. no. 5461, pp. 2136 - 2138
DOI: 10.1126/science.287.5461.2136
Prev | Table of Contents | Next

News Focus

PROTEOMICS
Can Celera Do It Again?

Robert F. Service

The upstart Celera Genomics of Rockville, Maryland, is set to embark on an ambitious new effort to move beyond the human genome to conquer the next frontier: "proteomics," the effort to identify all the proteins expressed in an organism and then track their ebb and flow, a crucial step in developing novel drugs and tailoring medical care to the genetic makeup of individuals. To pay for the new initiative, Celera raised $944 million in a stock offering earlier this month, much of which will be devoted to proteomics. But Celera faces a huge challenge and some stiff competition from companies already in the field.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Biological mass spectrometry: a primer.
R. Bakhtiar and F.L.S. Tse (2000)
Mutagenesis 15, 415-430
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)